The San Clemente, Calif.-based company said it plans to float 1.2 million shares of its common stock at $2.05 per share. The offering also includes unregistered warrants to purchase an additional 1.2 million shares at approximately 13¢ per warrant, which the company said could bring in an additional $150,000.
Funds from the placement are slated to support continued commercialization, clinical and product development activities and for general corporate purposes, ReShape Lifesciences said.
The offering is expected to close on July 12, ReShape said. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering, according to a press release.
Last month, ReShape Lifesciences said it inked approximately $1.5 million in offering deals with a number of institutional investors.
Heidi Dohse was diagnosed with a rare arrhythmia in 1982 and has been 100% pacemaker dependent for over 30 years. With the help of wearable devices, she has been able to pursue her dream to become a competitive cyclist.
You can hear her story and more when you register for DeviceTalks Boston, October 8-10.
Use code FINISHLINE to save an additional 10%.